{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:47:38Z","timestamp":1773434858177,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific Research Project of Nanxishan Hospital of Guangxi Zhuang Autonomous Region","award":["NY202005"],"award-info":[{"award-number":["NY202005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02712-y","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T17:29:18Z","timestamp":1746466158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Serum hepatitis B virus RNA in low-level viremia of chronic hepatitis B: clinical features and association with virological response"],"prefix":"10.1186","volume":"22","author":[{"given":"Yongbin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guifang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"issue":"3","key":"2712_CR1","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/hep.27889","volume":"62","author":"DH Sinn","year":"2015","unstructured":"Sinn DH, Lee J, Goo J, Kim K, Gwak GY, Paik YH, et al. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology. 2015;62(3):694\u2013701. https:\/\/doi.org\/10.1002\/hep.27889.","journal-title":"Hepatology"},{"issue":"2","key":"2712_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/hep.28916","volume":"66","author":"JH Kim","year":"2017","unstructured":"Kim JH, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving Entecavir treatment. Hepatology. 2017;66(2):335\u201343. https:\/\/doi.org\/10.1002\/hep.28916.","journal-title":"Hepatology"},{"key":"2712_CR3","doi-asserted-by":"crossref","unstructured":"Wang X, Cai D, Juan Z. Low-level viremia in patients with chronic hepatitis B receiving Entecavir, Tenofovir and Tenofovir Alafenamide. J Hepatol. 2022.","DOI":"10.1016\/S0168-8278(22)02049-9"},{"issue":"23","key":"2712_CR4","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1097\/CM9.0000000000001793","volume":"134","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Cai DC, Hu P, Ren H. Low-level viremia in nucleoside analog-treated chronic hepatitis B patients. Chin Med J (Engl). 2021;134(23):2810\u20137. https:\/\/doi.org\/10.1097\/CM9.0000000000001793.","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"2712_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","volume":"66","author":"CL Lai","year":"2017","unstructured":"Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66(2):275\u201381. https:\/\/doi.org\/10.1016\/j.jhep.2016.08.022.","journal-title":"J Hepatol"},{"key":"2712_CR6","doi-asserted-by":"publisher","unstructured":"[The guidelines of prevention and treatment for chronic hepatitis B. (2019 version)]. Zhonghua Gan Zang Bing Za Zhi. 2019;27(12):938\u201361. https:\/\/doi.org\/10.3760\/cma.j.issn.1007-3418.2019.12.007","DOI":"10.3760\/cma.j.issn.1007-3418.2019.12.007"},{"issue":"2","key":"2712_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cgh.2024.07.024","volume":"23","author":"S Liu","year":"2025","unstructured":"Liu S, Wong GL, Fan R, Niu J, Ma H, Liang W, et al. Role of early On-Treatment serum HBV RNA declines in predicting hepatocellular carcinoma risk in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2025;23(2):291\u2013e915. https:\/\/doi.org\/10.1016\/j.cgh.2024.07.024.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2712_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/cld.728","volume":"12","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Clin Liver Dis (Hoboken). 2018;12(1):33\u20134. https:\/\/doi.org\/10.1002\/cld.728.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"12","key":"2712_CR9","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.cgh.2018.09.010","volume":"16","author":"N Terrault","year":"2018","unstructured":"Terrault N. Is low level viremia acceptable during antiviral therapy of patients with HBV infection and decompensated cirrhosis?? Clin Gastroenterol Hepatol. 2018;16(12):1876\u20138. https:\/\/doi.org\/10.1016\/j.cgh.2018.09.010.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2712_CR10","doi-asserted-by":"publisher","unstructured":"EASL. 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021","DOI":"10.1016\/j.jhep.2017.03.021"},{"issue":"10","key":"2712_CR11","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/apt.16097","volume":"52","author":"JH Kao","year":"2020","unstructured":"Kao JH, Hu TH, Jia J, Kurosaki M, Lim YS, Lin HC, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B. Aliment Pharmacol Ther. 2020;52(10):1540\u201350. https:\/\/doi.org\/10.1111\/apt.16097.","journal-title":"Aliment Pharmacol Ther"},{"issue":"17","key":"2712_CR12","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.3748\/wjg.v30.i17.2294","volume":"30","author":"F Di Dato","year":"2024","unstructured":"Di Dato F, Iorio R. Expanding indications for chronic hepatitis B treatment: is it really desirable to treat everyone? World J Gastroenterol. 2024;30(17):2294\u20137. https:\/\/doi.org\/10.3748\/wjg.v30.i17.2294.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2712_CR13","doi-asserted-by":"publisher","first-page":"970","DOI":"10.14309\/ajg.0000000000002224","volume":"118","author":"MG Ghany","year":"2023","unstructured":"Ghany MG, Saraswat VA. Patients with compensated hepatitis B Virus-Related cirrhosis and Low-Level viremia: treat or not to treat? Am J Gastroenterol. 2023;118(6):970\u20131. https:\/\/doi.org\/10.14309\/ajg.0000000000002224.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2712_CR14","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.14309\/ajg.0000000000002181","volume":"118","author":"J Yang","year":"2023","unstructured":"Yang J, Choi WM, Shim JH, Lee D, Kim KM, Lim YS, et al. Low level of hepatitis B viremia compared with undetectable viremia increases the risk of hepatocellular carcinoma in patients with untreated compensated cirrhosis. Am J Gastroenterol. 2023;118(6):1010\u20138. https:\/\/doi.org\/10.14309\/ajg.0000000000002181.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2712_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3350\/cmh.2020.0012","volume":"26","author":"SB Lee","year":"2020","unstructured":"Lee SB, Jeong J, Park JH, Jung SW, Jeong ID, Bang SJ, et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to Entecavir. Clin Mol Hepatol. 2020;26(3):364\u201375. https:\/\/doi.org\/10.3350\/cmh.2020.0012.","journal-title":"Clin Mol Hepatol"},{"issue":"7","key":"2712_CR16","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/ajg.2011.45","volume":"106","author":"MF Yuen","year":"2011","unstructured":"Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous Entecavir therapy in treatment-na\u00efve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106(7):1264\u201371. https:\/\/doi.org\/10.1038\/ajg.2011.45.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2712_CR17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jhep.2012.04.037","volume":"57","author":"A Ono","year":"2012","unstructured":"Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, et al. Long-term continuous Entecavir therapy in nucleos(t)ide-na\u00efve chronic hepatitis B patients. J Hepatol. 2012;57(3):508\u201314. https:\/\/doi.org\/10.1016\/j.jhep.2012.04.037.","journal-title":"J Hepatol"},{"issue":"8","key":"2712_CR18","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/apt.16788","volume":"55","author":"YS Lim","year":"2022","unstructured":"Lim YS, Seto WK, Kurosaki M, Fung S, Kao JH, Hou J, et al. Review Article: switching patients with chronic hepatitis B to Tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther. 2022;55(8):921\u201343. https:\/\/doi.org\/10.1111\/apt.16788.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2712_CR19","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/apt.17107","volume":"56","author":"E Ogawa","year":"2022","unstructured":"Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, et al. Switching to Tenofovir Alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. Aliment Pharmacol Ther. 2022;56(4):713\u201322. https:\/\/doi.org\/10.1111\/apt.17107.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"2712_CR20","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/liv.14786","volume":"41","author":"ZB Li","year":"2021","unstructured":"Li ZB, Li L, Niu XX, Chen SH, Fu YM, Wang CY, et al. Switching from Entecavir to Tenofovir Alafenamide for chronic hepatitis B patients with low-level viraemia. Liver Int. 2021;41(6):1254\u201364. https:\/\/doi.org\/10.1111\/liv.14786.","journal-title":"Liver Int"},{"issue":"11","key":"2712_CR21","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1016\/j.cgh.2020.03.001","volume":"18","author":"Y Sun","year":"2020","unstructured":"Sun Y, Wu X, Zhou J, Meng T, Wang B, Chen S, et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy. Clin Gastroenterol Hepatol. 2020;18(11):2582\u201391.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2712_CR22","doi-asserted-by":"publisher","first-page":"850","DOI":"10.14218\/jcth.2021.00046","volume":"9","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Peng H, Liu X, Wang H, Du J, Luo X, et al. Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease. J Clin Transl Hepatol. 2021;9(6):850\u20139. https:\/\/doi.org\/10.14218\/jcth.2021.00046.","journal-title":"J Clin Transl Hepatol"},{"issue":"8","key":"2712_CR23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/jvh.13957","volume":"31","author":"T Li","year":"2024","unstructured":"Li T, Chen Y, Zhang Y, Wu S, Zhang L, Wang L. Elevated hepatitis B virus RNA levels in HBeAg-positive patients with low-level viraemia or previous low-level viraemia. J Viral Hepat. 2024;31(8):504\u20137. https:\/\/doi.org\/10.1111\/jvh.13957.","journal-title":"J Viral Hepat"},{"issue":"5","key":"2712_CR24","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/apt.17105","volume":"56","author":"J Lok","year":"2022","unstructured":"Lok J, Dusheiko G, Carey I, Agarwal K. Review Article: novel biomarkers in hepatitis B infection. Aliment Pharmacol Ther. 2022;56(5):760\u201376. https:\/\/doi.org\/10.1111\/apt.17105.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2712_CR25","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1097\/hep.0000000000000413","volume":"78","author":"MG Ghany","year":"2023","unstructured":"Ghany MG, King WC, Hinerman AS, Lok AS, Lisker-Melman M, Chung RT, et al. Use of HBV RNA and to predict change in serological status and disease activity in CHB. Hepatology. 2023;78(5):1542\u201357. https:\/\/doi.org\/10.1097\/hep.0000000000000413.","journal-title":"Hepatology"},{"key":"2712_CR26","doi-asserted-by":"publisher","unstructured":"Thompson AJ, Jackson K, Bonanzinga S, Hall SAL, Hume S, Burns GS, et al. Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants. Hepatol Commun. 2023;7(8). https:\/\/doi.org\/10.1097\/hc9.0000000000000188.","DOI":"10.1097\/hc9.0000000000000188"},{"key":"2712_CR27","doi-asserted-by":"publisher","unstructured":"Shi L, Grace L-HW, Rong F, Junqi N, Hong M, Wanying L et al. Role of early on-treatment serum HBV RNA declines in predicting hepatocellular carcinoma risk in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2024(0). https:\/\/doi.org\/10.1016\/j.cgh.2024.07.024","DOI":"10.1016\/j.cgh.2024.07.024"},{"issue":"5","key":"2712_CR28","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jinf.2021.08.044","volume":"83","author":"Y Wu","year":"2021","unstructured":"Wu Y, Wen J, Tang G, Zhang J, Xin J. On-treatment HBV RNA dynamic predicts entecavir-induced hbeag seroconversion in children with chronic hepatitis B. J Infect. 2021;83(5):594\u2013600. https:\/\/doi.org\/10.1016\/j.jinf.2021.08.044.","journal-title":"J Infect"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02712-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02712-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02712-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T17:29:20Z","timestamp":1746466160000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02712-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2712"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02712-y","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective analysis of de-identified clinical data and archived samples was conducted under ethical approval (2020NXSYYEC-003) with a waiver of informed consent, in accordance with the Declaration of Helsinki guidelines for minimal-risk research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}